Difficulty: Medium
Average Score: 74%
Practice
At high (but not necessarily toxic) blood levels, a cardiovascular drug with which you should be familiar causes many signs and symptoms that resemble what you see with 'low-grade' aspirin toxicity (salicylism): light-headedness, tinnitus, and visual disturbances such as diplopia. What is the most likely drug that caused these responses?
Correct answer
D
Rationale
The most likely drug causing the symptoms described is Quinidine. Quinidine is a Class I antiarrhythmic drug that can lead to cinchonism, a syndrome caused by high blood levels of quinidine. Cinchonism symptoms include tinnitus, visual disturbances like diplopia, and light-headedness, resembling low-grade aspirin toxicity (salicylism).
Atropine (Option A) is a parasympatholytic drug used to increase heart rate and dilate pupils; it does not cause symptoms similar to cinchonism. Captopril (Option B) is an ACE inhibitor used for hypertension, which does not induce cinchonism symptoms. Propranolol (Option C) is a beta-blocker that can cause bradycardia and bronchospasm but not the specific symptoms described.
Understanding the side effects and toxicities of cardiovascular drugs is crucial for healthcare professionals to ensure safe medication administration and patient care. Recognizing the unique symptoms associated with each drug class helps in prompt identification and management of adverse reactions.
Atropine (Option A) is a parasympatholytic drug used to increase heart rate and dilate pupils; it does not cause symptoms similar to cinchonism. Captopril (Option B) is an ACE inhibitor used for hypertension, which does not induce cinchonism symptoms. Propranolol (Option C) is a beta-blocker that can cause bradycardia and bronchospasm but not the specific symptoms described.
Understanding the side effects and toxicities of cardiovascular drugs is crucial for healthcare professionals to ensure safe medication administration and patient care. Recognizing the unique symptoms associated with each drug class helps in prompt identification and management of adverse reactions.